Registry for Korean patients with borderline ovarian tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to collect comprehensive data on Korean patients diagnosed with borderline ovarian tumors (BOTs). Researchers will retrospectively gather information from medical records of patients treated between November 1994 and February 2015, and prospectively collect data from patients treated since March 2015. The data will include various clinical parameters such as age, body mass index, and treatment outcomes, which will be updated every six months to monitor disease progression and follow-up care. This initiative seeks to enhance understanding and management of BOTs in the Korean population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea.
* All patients undergoing gynecologic surgery for BOTs at institutions where placed in the Republic of Korea since March, 2015

Exclusion Criteria:

* Patients who did not receive primary treatment or follow-up for at least 6 months at each institution were excluded from analysis

Where it's running

• Samsung Changwon Hospital
  Changwon, South Korea Recruiting
• Kangbuk Samsung Hospital
  Seoul, South Korea Recruiting
• CHA Gangnam Medical Center
  Seoul, South Korea Recruiting
• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Taejong Song, MD, PhD — Kangbuk Samsung Hospital
• Study coordinator: Taejong Song, MD,PhD
• Email: taejong.song@gmail.com
• Phone: 82-2-2001-2582

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Mo-Rez maintenance therapy in first-line ovarian cancer

  This study tests mocertatug rezetecan (Mo-Rez) alone or with bevacizumab to see if it helps people with newly diagnosed advanced ovarian cancer, compared with bevacizumab alone or no active treatment after initial chemotherapy.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Buenos Aires and 11 other locations · NCT07694427

• Mocertatug Rezetecan with Bevacizumab vs Platinum Doublet with Bevacizumab in Platinum-Sensitive Ovarian Cancer

  This trial tests whether mocertatug rezetecan plus bevacizumab helps people with platinum-sensitive ovarian cancer respond better than standard platinum-based therapy plus bevacizumab.

  Recruiting at 9 sites Phase 3 GlaxoSmithKline · Newcastle, New South Wales and 8 other locations · NCT07684612

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Mocertatug Rezetecan vs Standard Care for Platinum-Resistant Ovarian Cancer

  This study tests mocertatug rezetecan (Mo-Rez) against standard treatments to see if it helps people with platinum-resistant ovarian cancer behave better and handle side effects.

  Recruiting at 22 sites Phase 3 GlaxoSmithKline · Randwick, New South Wales and 21 other locations · NCT07286266

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.